Portola Pharmaceuticals is a biopharmaceutical company that discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular and autoimmune/inflammatory diseases. Portola scientists have successfully collaborated for over 15 years on the discovery and development of novel small molecule agents targeting platelets, coagulation pathways and protein kinases. Portola has independently initiated a Phase 3 study of its lead molecule, betrixaban, a novel, once-daily Factor Xa inhibitor for venous thromboembolism (VTE) prevention in acute medically ill patients. Learn More